Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 3
2005 3
2006 3
2016 1
2017 2
2018 1
2019 2
2020 2
2022 2
2023 2
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study.
Lopez-Tarruella S, Del Monte-Millán M, Roche-Molina M, Jerez Y, Echavarria Diaz-Guardamino I, Herrero López B, Gamez Casado S, Marquez-Rodas I, Alvarez E, Cebollero M, Massarrah T, Ocaña I, Arias A, García-Sáenz JÁ, Moreno Anton F, Olier Garate C, Moreno Muñoz D, Marrupe D, Lara Álvarez MÁ, Enrech S, Bueno Muiño C, Martín M. Lopez-Tarruella S, et al. Among authors: moreno anton f. Breast Cancer Res Treat. 2024 Jan;203(1):163-172. doi: 10.1007/s10549-023-07094-9. Epub 2023 Sep 29. Breast Cancer Res Treat. 2024. PMID: 37773555 Free PMC article.
[Non surgical pneumoperitoneum].
Moreno Antón F, García-Donas J. Moreno Antón F, et al. Rev Clin Esp. 2004 Jul;204(7):372-4. doi: 10.1157/13063530. Rev Clin Esp. 2004. PMID: 15274784 Spanish. No abstract available.
Clinical Experience with Abemaciclib in Patients Previously Treated with Another CDK 4/6 Inhibitor in a Tertiary Hospital: A Case Series Study.
de Luna Aguilar AM, Fuentes JDB, Ortega Anselmi J, Olalla Inoa J, Flores Navarro P, Lopez de Sá A, Fuentes Antras J, Rodríguez Rey C, Ortega Candil A, Moreno Antón F, García Sáenz JÁ. de Luna Aguilar AM, et al. Among authors: moreno anton f. Cancers (Basel). 2023 Sep 7;15(18):4452. doi: 10.3390/cancers15184452. Cancers (Basel). 2023. PMID: 37760421 Free PMC article.
The economic burden of metastatic breast cancer in Spain.
Bermejo de Las Heras B, Cortes Ramon Y Cajal J, Galve Calvo E, de la Haba Rodriguez J, Garcia Mata J, Moreno Anton F, Pelaez Fernandez I, Rodriguez-Lescure A, Rodriguez Sanchez CA, Ruiz-Borrego M, Remak E, Barra M, Rivero M, Soto Alvarez J. Bermejo de Las Heras B, et al. Among authors: moreno anton f. Eur J Hosp Pharm. 2020 Jan;27(1):19-24. doi: 10.1136/ejhpharm-2017-001453. Epub 2018 Jul 30. Eur J Hosp Pharm. 2020. PMID: 32064084 Free PMC article.
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2- advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial.
Salvador Bofill J, Moreno Anton F, Rodriguez Sanchez CA, Galve Calvo E, Hernando Melia C, Ciruelos Gil EM, Vidal M, Jiménez-Rodriguez B, De la Cruz Merino L, Martínez Jañez N, Villanueva Vazquez R, de Toro Salas R, Anton Torres A, Alvarez Lopez IM, Gavila Gregori J, Quiroga Garcia V, Vicente Rubio E, De la Haba-Rodriguez J, Gonzalez-Santiago S, Diaz Fernandez N, Barnadas Molins A, Cantos Sanchez de Ibargüen B, Delgado Mingorance JI, Bellet Ezquerra M, de Casa S, Gimeno A, Martin M. Salvador Bofill J, et al. Among authors: moreno anton f. Breast. 2022 Dec;66:77-84. doi: 10.1016/j.breast.2022.09.006. Epub 2022 Sep 28. Breast. 2022. PMID: 36206609 Free PMC article. Clinical Trial.
Case report: Clinical success targeting BRAF-mutated, hormone receptor positive, HER2- negative advanced breast cancer patient with BRAF-inhibitor plus MEK- inhibitor.
López de Sá A, de Luna A, Antoñanzas M, García-Barberán V, Moreno-Anton F, García-Sáenz JA. López de Sá A, et al. Among authors: moreno anton f. Front Oncol. 2022 Dec 2;12:997346. doi: 10.3389/fonc.2022.997346. eCollection 2022. Front Oncol. 2022. PMID: 36531075 Free PMC article.
Critically short telomeres and toxicity of chemotherapy in early breast cancer.
Quintela-Fandino M, Soberon N, Lluch A, Manso L, Calvo I, Cortes J, Moreno-Antón F, Gil-Gil M, Martinez-Jánez N, Gonzalez-Martin A, Adrover E, de Andres R, Viñas G, Llombart-Cussac A, Alba E, Mouron S, Guerra J, Bermejo B, Zamora E, García-Saenz JA, Simon SP, Carrasco E, Escudero MJ, Campo R, Colomer R, Blasco MA. Quintela-Fandino M, et al. Among authors: moreno anton f. Oncotarget. 2017 Mar 28;8(13):21472-21482. doi: 10.18632/oncotarget.15592. Oncotarget. 2017. PMID: 28423524 Free PMC article. Clinical Trial.
Breast metastases as the first sign of recurrence of a cutaneous melanoma.
Sampedro Gimeno T, Moreno Antón F, López-Tarruella Cobo S, González Larriba JL, Furio Bacete V, Díaz-Rubio García E. Sampedro Gimeno T, et al. Among authors: moreno anton f. Clin Transl Oncol. 2006 Jan;8(1):57-9. doi: 10.1007/s12094-006-0097-6. Clin Transl Oncol. 2006. PMID: 16632442
18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial.
Quintela-Fandino M, Lluch A, Manso L, Calvo I, Cortes J, García-Saenz JA, Gil-Gil M, Martinez-Jánez N, Gonzalez-Martin A, Adrover E, de Andres R, Viñas G, Llombart-Cussac A, Alba E, Guerra J, Bermejo B, Zamora E, Moreno-Anton F, Pernas Simon S, Carrato A, Lopez-Alonso A, Escudero MJ, Campo R, Carrasco E, Palacios J, Mulero F, Colomer R. Quintela-Fandino M, et al. Among authors: moreno anton f. Clin Cancer Res. 2017 Mar 15;23(6):1432-1441. doi: 10.1158/1078-0432.CCR-16-0738. Epub 2016 Sep 1. Clin Cancer Res. 2017. PMID: 27587436 Free article. Clinical Trial.
18 results